Persistence with treatment in patients with Wilson disease
Authors:
- Grzegorz ChabikGCGrzegorz Chabik
- Anna CzłonkowskaACAnna Członkowska
- 1 January 2010
- journal article
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 44 (3) , 260-263
Abstract
Wilson disease is genetically induced failure of copper metabolism. If untreated, it may lead to death within several years from the onset of symptoms. Use of medication should therefore continue over the whole span of the patient's life after the diagnosis. Clinical observations show that patients with Wilson disease frequently stop the treatment. The aim of our study was to assess how drug compliance (defined as persistence with drug use) translates into the total well-being of patients with Wilson disease. Patients diagnosed with Wilson disease and observed in our outpatient clinics were asked to fill in the self-completed questionnaire. Questions were related to demographic data, characteristics of the disease, methods of treatment and persistence with treatment, subjective assessment of health status and treatment efficacy. The EQ-5D questionnaire with a visual analogue scale of well-being was also used. Responses were obtained from 120 subjects but only 104 questionnaires could be further processed. Our analysis did not reveal differences in persistence with d-penicillamine and zinc sulphate use or efficacy of prescribed medication. We found, however, that regardless of the medication used, persistence with treatment resulted in significantly better results of self-assessment (total improvement in 39.7% vs. 7.7% in the non-persistent group, p = 0.003; partial improvement in 53.8% vs. 30.8%, respectively, p = 0.045; and deterioration: none in the persistent group vs. 42.3% in the non-persistent group, p < 0.0001). Lack of persistence with use of prescribed medication is rather frequent among patients with Wilson disease. Lack of compliance decreases chances for improvement and might be the cause of clinical deterioration.Keywords
This publication has 12 references indexed in Scilit:
- TheCostsof ComplianceThe Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 2007
- Wilson's diseaseThe Lancet, 2007
- Neurological manifestations in Wilson's disease: Report of 119 casesMovement Disorders, 2006
- A meta-analysis of the association between adherence to drug therapy and mortalityBMJ, 2006
- Adherence and outcomes: it's more than taking the pillsThe Lancet, 2005
- Wilson’s disease—cause of mortality in 164 patients during 1992–2003 observation periodJournal of Neurology, 2005
- Depression Is a Risk Factor for Noncompliance With Medical TreatmentArchives of internal medicine (1960), 2000
- The interaction of patient perception of overmedication with drug compliance and side effectsJournal of General Internal Medicine, 1998
- Compliance with treatment regimens in chronic asymptomatic diseasesThe American Journal of Medicine, 1997
- Effects of long-term treatment in Wilson's disease withd-penicillamine and zinc sulphateJournal of Neurology, 1996